Humatrope is a medicine containing the active ingredient(s) somatropin. On this page you will find out more about Humatrope, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: somatropin
Over 65 years of age?
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Humatrope (1 x 24 mg cartridge, 1 x 3.15 mL inert diluent syringe), 1 pack
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
HUMATROPE is indicated for the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.,HUMATROPE is also indicated for the treatment of growth disturbances associated with gonadal dysgenesis (Turner syndrome).,HUMATROPE is also indicated for the treatment of adults with severe growth hormone deficiency defined as patients with known hypothalamic-pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth deficiency. In patients with childhood onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranal irradiation), two dynamic tests should be recommended, except for those having low IGF-I concentrations less than or equal to 2 SDS who may be considered for one test. The cut-off point of the dynamic test should be strict.,HUMATROPE is also indicated for the treatment of growth retardation in prepubertal children with chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. Chronic renal insufficiency is defined as glomerular filtration rate of less than 30 mL/min/1.73 m2.,HUMATROPE is also indicated for the treatment of growth failure in children born small for gestational age (SGA) who fail to demonstrate catch-up growth by age two to four years (see CLINICAL TRIALS).
Table of characteristics
1 cartridge of powder - 72IU (24mg): Prescription Only Medicine, or Prescription Animal Remedy
1 syringe with diluent 3.15mL: Not scheduled. Not considered by committee
|Visual appearance||Clear liquid.|
|Dosage Form||Injection, solution|
|Route of administration||Intramuscular|
|Visual appearance||White or almost white powder.|
|Dosage Form||Injection, powder for|
|Route of administration||Intramuscular|
There is one type of pack available.
Pack type 1
|Storage temperature||Store at 2 to 8 degrees Celsius|
|Storage conditions||Refrigerate,Do not Freeze|
|Life time||3 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 November 2017
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 2 results
Humatrope | myVMC
Humatrope is a medicine used to treat short stature caused by low levels of growth hormones and/or medical conditions. It contains omatropin.
Read more on myVMC – Virtual Medical Centre website
Humatrope Powder for injection - myDr.com.au
Humatrope Powder for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 0 results